Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation System-

Inclusion Criteria: * \> = 18 years of age * Must be found to have locally advanced unresectable disease following standard chemotherapy ± radiotherapy as demonstrated with either CT/MRI imaging and surgical evaluation, and not have taken any chemotherapy/radiotherapy within 5 weeks of treatment with the NanoKnife IRE System * Must have an INR \< 1.5 * Are willing and able to comply with the protocol requirements * Are able to comprehend and willing to sign an informed consent form Exclusion Criteria: * Creatinine \> 2.0 mg/dL * Any lab value with a grade 3 or 4 toxicity as defined by the CTCAE Version 5.0 * Inability to stop antiplatelet and coumadin therapy for 7 days prior to and 7 days post treatment with the NanoKnife System * Tumor size not measurable * Known history of contrast allergy that cannot be medically managed * Known hypersensitivity to the metal in the electrodes (stainless steel 304L) that cannot be medically managed * Unable to be treated with a muscle blockade agent (e.g. pancuronium bromide, atracurium, cisatracurium, etc.) * Women who are pregnant or currently breast feeding * Women of childbearing potential who are not utilizing an acceptable method of contraception * Have taken an investigational agent within 30 days of visit 1 * Have implanted cardiac pacemakers or defibrillators * Have implanted electronic devices or implants with metal parts in the vicinity of a lesion * Have a history of epilepsy or cardiac arrhythmia (atrial or ventricular fibrillation) * Have a recent history of myocardial infarction (within the past 2 months) * Have Q-T intervals greater than 550 ms unless treated with an Accysync Model 72 synchronization system controlling the NanoKnife system's output pulses * Evidence of distant metastases of stage IV * Have taken any chemotherapeutic agent within 5 weeks of treatment with the NanoKnife Irreversible Electroporation (IRE) System * Received non-conventional fractionation schedules, such as stereotactic radiation (5 fractions or less) or received higher than 54 Gray (Gy) delivered conventionally